HPV and therapeutic vaccines: Where are we in 2010?

Current Cancer Therapy Reviews

Volumn 6, Issue 2, 2010, Pages 81-103

  Ma, Barbara ^a   Xu, Yijie ^a   Hung, Chien Fu ^a,b   Wu, T C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cervical cancer; Clinical trials; Hpv; Therapeutic vaccine

Indexed keywords

ADXS 11 001; AMOLIMOGENE BEPIPLASMID; APIGENIN; BACTERIAL VECTOR; DENDRITIC CELL VACCINE; DNA VACCINE; E2 PROTEIN; EPIGALLOCATECHIN GALLATE; FLT3 LIGAND; FLUOROURACIL; HEAT SHOCK PROTEIN 70; HLA ANTIGEN; IMIQUIMOD; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NUCLEIC ACID; PROTEIN E6; PROTEIN E7; SGN 00101; TG 4001; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VGX 3100; VIRUS ANTIGEN; VIRUS DNA; VIRUS RNA; VIRUS VECTOR; WART VIRUS VACCINE; ZYC 101;

ABSENCE OF SIDE EFFECTS; ANAL INTRAEPITHELIAL NEOPLASIA; ANORECTAL INTRAEPITHELIAL NEOPLASIA; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CYTOTOXIC T LYMPHOCYTE; DNA REPLICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ELECTROPORATION; EPITHELIUM TUMOR; FEVER; GENE GUN; HIGH GRADE SQUAMOUS INTRAEPITHELIAL; HUMAN; HYPOTENSION; IMMUNOGENICITY; IMMUNOMODULATION; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; LISTERIA MONOCYTOGENES; MOLECULAR BIOLOGY; PAPILLOMATOSIS; PRIORITY JOURNAL; RECURRENT CANCER; REPLICON; RESPIRATORY PAPILLOMATOSIS; SALMONELLA ENTERICA; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINIA VIRUS; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRION; VIRUS ENTRY; VIRUS LIKE AGENT; VULVAR INTRAEPITHELIAL NEOPLASIA; WART VIRUS;

EID: 77952940985     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791202583     Document Type: Article

References (202)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324(1): 17-27.
4. Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. J Formos Med Assoc 2008; 107(3): 198-217.
5. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2(5): 342-50.
6. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89(24): 12180-4.
7. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67(12): 6929-36.
8. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6(10): 753-63.
9. Roden RB, Monie A, Wu TC. Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med 2007; 7(5): 490-503.
10. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 2009; 12(5-6): 319-30.
11. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24(27-28): 5571-83.
12. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5): 271-8.
13. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367(9518): 1247-55.
14. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175(11): 7297-302.
15. Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cellsurface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. Journal of drug targeting 2005; 13(2): 89-98.
16. Echchannaoui H, Bianchi M, Baud D, Bobst M, Stehle JC, Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun 2008; 76(5): 1940-51.
17. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 2002; 102(6): 629-37.
18. Sewell DA, Douven D, Pan ZK, Rodriguez A, Paterson Y. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg 2004; 130(1): 92-7.
19. Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008; 26(41): 5315-20.
20. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001; 167(11): 6471-9.
21. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27(30): 3975-83.
22. Sewell DA, Shahabi V, Gunn GR, 3rd, Pan ZK, Dominiecki ME, Paterson Y. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 2004; 64(24): 8821-5.
23. Zurkova K, Babiarova K, Hainz P, et al. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep 2009; 21(5): 1335-43.
24. Hsieh CJ, Kim TW, Hung CF, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004; 22(29-30): 3993-4001.
25. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007; 56(7): 997-1007.
26. Lee DW, Anderson ME, Wu S, Lee JH. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Arch Otolaryngol Head Neck Surg 2008; 134(12): 1316-23.
27. Zhou L, Zhu T, Ye X, et al. Long-term protection against HPV E7-positive tumor by a single vaccination of AAV vectors encoding a fusion protein of inactivated E7 of HPV 16/18 and heat shock protein 70. Hum Gene Ther 2009 (in press).
28. Liao JB, Publicover J, Rose JK, DiMaio D. Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. Clin Vaccine Immunol 2008; 15(5): 817-24.
29. Brandsma JL, Shlyankevich M, Su Y, Zelterman D, Rose JK, Buonocore L. Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors. Vaccine 2009 (in press).
30. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347(9014): 1523-7.
31. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002; 8(12): 3676-85.
32. Baldwin PJ, van der Burg SH, Boswell CM, et al. Vacciniaexpressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003; 9(14): 5205-13.
33. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63(18): 6032-41.
34. NIH. Surgery and Vaccine Therapy in Treating Patients with Early Cervical Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited 2009 Nov 3]. Available from: http://clinicaltrials.gov/show/NCT00002916 NLM Identifier: NCT00002916
35. Corona GCM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15(5): 421-31.
36. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Curr Gene Ther 2006; 13(6): 592-7.
37. Albarran YCA, de la Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. Biodrugs 2007; 21(1): 47-59.
38. TG 4001/R3484 (MVA-HPV-IL2). 2009 [cited 2009 Nov 13]; Available from: http://www.transgene.fr/us/product_pipeline/ iframe_mva_hpv_il2.htm
39. Chang CL, Ma B, Pang X, Wu TC, Hung CF. Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther 2009; 17(8): 1365-72.
40. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23(9): 2242-9.
41. Liu DW, Yang YC, Lin HF, et al. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. J Virol 2007; 81(6): 2869-79.
42. Sharma RK, Elpek KG, Yolcu ES, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009; 69(10): 4319-26.
43. Chen YF, Lin CW, Tsao YP, Chen SL. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpGoligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004; 78(3): 1333-43.
44. Daftarian P, Mansour M, Benoit AC, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006; 24(24): 5235-44.
45. Daftarian PM, Mansour M, Pohajdak B, et al. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med 2007; 5: 26.
46. Manuri PR, Nehete B, Nehete PN, et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007; 25(17): 3302-10.
47. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 2008; 57(4): 517-30.
48. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4(9): 2103-9.
49. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35(6): 946-52.
50. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000; 23(2): 255-66.
51. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6(9): 3406-16.
52. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169(1): 350-8.
53. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005; 23(45): 5271-80.
54. Melief CJ, Welters MJ, Lowik MJ, Vloon AP, Kenter GG. Long peptide vaccine-induced migration of HPV16-specific type 1 and 2 T cells into the lesions of VIN III patients associated with complete clinical responses. Cancer Immun 2007; 7(Suppl.1): 20.
55. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14(1): 169-77.
56. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumorspecific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14(1): 178-87.
57. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361(19): 1838-47.
58. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005; 54(12): 1180-90.
59. Stewart TJ, Drane D, Malliaros J, et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004; 22(27-28): 3738-43.
60. Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005; 65(2): 641-9.
61. Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones 2000; 5(5): 401-5.
62. Liu B, Ye D, Song X, et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 2008; 26(10): 1387-96.
63. Liao CW, Chen CA, Lee CN, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005; 65(19): 9089-98.
64. Thompson HS, Davies ML, Holding FP, et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999; 17(1): 40-9.
65. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999; 179(3): 612-8.
66. de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002; 20(29-30): 3456-64.
67. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 proteinbased vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004; 53(7): 642-50.
68. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23(2): 172-81.
69. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 2002; 45(4): 502-7.
70. Derkay CS, Smith RJ, McClay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an openlabel trial. Ann Otol Rhinol Laryngol 2005; 114(9): 730-7.
71. Palefsky JM, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIVpositive individuals. AIDS 2006; 20(8): 1151-5.
72. Roman LD, Wilczynski S, Muderspach LI, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007; 106(3): 558-66.
73. Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106(3): 453-60.
74. Van Doorslaer K, Reimers LL, Studentsov YY, Einstein MH, Burk RD. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol 2009.
75. NIH. Vaccine Therapy in Preventing Cervical Cancer in Patients with Cervical Intrapeithelial Neoplasia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited: 2009 Nov 11]. Available from: http: //clinicaltrials.gov/ show/NCT00054041 NLM Identifier: NCT00054041.
76. NCI. SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited: 2009 Nov 4]. Available from: http: //clinicaltrials.gov/ show/NCT00091130 NLM Identifier: NCT00091130.
77. Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004; 10(9): 2954-61.
78. Fiander AN, Tristram AJ, Davidson EJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006; 16(3): 1075-81.
79. Davidson EJ, Faulkner RL, Sehr P, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004; 22(21-22): 2722-9.
80. van der Burg SH, Kwappenberg KM, O'Neill T, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001; 19(27): 3652-60.
81. Nventa. A Multicenter, Nonrandomized, Open-Label Phase I Safety Study of HspE7 and Poly-ICLC Administered Concomittantly in Cervical Intrapeithelial Neoplasia (CIN) Subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008-[cited: 2009 Nov 20]. Available from: http://clinicaltrials.gov/show/NCT00493545 NLM Identifier: NCT00493545
82. Nventa Announces Additional Positive Immunological Data From HspE7 Phase I Cervical Dysplasia Trial. 2008 [cited: 2009 Nov 18]; Available from: http: //www.medicalnewstoday.com/articles/ 107158.php
83. Trimble C, Lin CT, Hung CF, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21(25-26): 4036-42.
84. Chen CA, Chang MC, Sun WZ, et al. Noncarrier naked antigenspecific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects. Gene Ther 2009; 16(6): 776-87.
85. Best SR, Peng S, Juang CM, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27(40): 5450-9.
86. Seo SH, Jin HT, Park SH, Youn JI, Sung YC. Optimal induction of HPV DNA vaccine-induced CD8(+) T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009 (in press).
87. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008; 26(40): 5210-5.
88. Mao CP, Hung CF, Kang TH, et al. Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency. J Virol 2010; 84: 2331-9.
89. VGX. Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3. In: ClinicalTrials. Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited 2009 Nov 6]. Available from: http://clinicaltrials.gov/show/NCT00685412 NLM Identifier: NCT00685412.
90. Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released. 2009 [cited: 2009 Nov 21]. Availble from: http: //www.news-medical.net/news/20091005/Phase-I-clinical -trial-results-to-test-the-safety-and-immunogenicity-of-VGX-3100-released.aspx
91. Zeira E, Manevitch A, Manevitch Z, et al. Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. FASEB J 2007; 21(13): 3522-33.
92. Tsen SW, Wu CY, Meneshian A, Pai SI, Hung CF, Wu TC. Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci 2009; 16: 36.
93. Hedley ML, Curley J, Urban R. Microspheres containing plasmidencoded antigens elicit cytotoxic T-cell responses. Nat Med 1998; 4(3): 365-8.
94. Storrie H, Mooney DJ. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Deliv Rev 2006; 58(4): 500-14.
95. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002; 8(5): 1028-37.
96. van den Berg JH, Nujien B, Beijnen JH, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20(3): 181-9.
97. Pokorna D, Rubio I, Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008; 6: 4.
98. Su X, Kim BS, Kim SR, Hammond PT, Irvine DJ. Layer-by-layerassembled multilayer films for transcutaneous drug and vaccine delivery. ACS Nano 2009; 3(11): 3719-29.
99. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009; 333: 369-93.
100. Alvarez-Salas LM. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Curr Opin Mol Ther 2008; 10(6): 622-8.
101. Sheets EE, Urban RG, Crum CP, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003; 188(4): 916-26.
102. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103(2): 317-26.
103. Eisai. A Study of Amolimogene (ZYC101a) in Patients with High Grade Cervical Intraepithelial Lesions of the Uterine Cervix. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited: 2009 Nov 23]. Available from: http: //clinicaltrials.gov/show/NCT00264732 NLM Identifier: NCT00264732
104. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16(5): 440-3.
105. Dilber MS, Phelan A, Aints A, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6(1): 12-21.
106. Wybranietz WA, Gross CD, Phelan A, et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001; 8(21): 1654-64.
107. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88(2): 223-33.
108. Kim TW, Hung CF, Kim JW, et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 2004; 15(2): 167-77.
109. Hung CF, Cheng WF, Chai CY, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166(9): 5733-40.
110. Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002; 76(6): 2676-82.
111. Hung CF, Hsu KF, Cheng WF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001; 61(3): 1080-8.
112. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60(4): 1035-42.
113. Zong J, Peng Q, Wang Q, Zhang T, Fan D, Xu X. Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects. Oncol Rep 2009; 22(4): 953-61.
114. Lin CT, Tsai YC, He L, et al. A DNA vaccine encoding a codonoptimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 2006; 13(4): 481-8.
115. Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 2003; 77(8): 4928-37.
116. Yan J, Reichenbach DK, Corbitt N, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27(3): 431-40.
117. Hirasawa Y, Arai M, Imazeki F, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology 2006; 71(1-2): 77-85.
118. Lu D, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009; 27(32): 4363-9.
119. Hung CF, Cheng WF, He L, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003; 63(10): 2393-8.
120. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108(5): 669-78.
121. Peng S, Trimble C, Ji H, et al. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci 2005; 12(5): 689-700.
122. Kim D, Gambhira R, Karanam B, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008; 26(3): 351-60.
123. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15(1): 361-7.
124. NCI. Vaccine Therapy With or Without Imiquimod in Treating Patients with Grade 3 Cervical Intraepithelial Neoplasia. In: ClinicalTrials. Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited: 2009 Nov 14]. Available from: http: //clinicaltrials.gov/show/NCT00788164 NLM Identifier: NCT00788164
125. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995; 92(25): 11671-5.
126. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999; 10(17): 2727-40.
127. Hung CF, Tsai YC, He L, Wu TC. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther 2007; 15(6): 1211-9.
128. Kim D, Monie A, He L, Tsai YC, Hung CF, Wu TC. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther 2008; 15(9): 677-87.
129. Kim D, Hoory T, Wu TC, Hung CF. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther 2007; 18(11): 1129-39.
130. Kim D, Monie A, Tsai YC, et al. Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigenspecific immune responses in vaccinated mice. Gene Ther 2008; 15(16): 1176-83.
131. Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008; 26(26): 3362-70.
132. Hung CF, Cheng WF, Hsu KF, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61(9): 3698-703.
133. Kang TH, Chung JY, Monie A, Pai SI, Hung CF, Wu TC. Enhancing DNA vaccine potency by co-administration of xenogenic MHC-class-I DNA. Gene Ther 2009 (in press).
134. Huang CH, Peng S, He L, et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005; 12(15): 1180-6.
135. Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008; 180(10): 7019-27.
136. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003; 112(1): 109-17.
137. Cheng WF, Chang MC, Sun WZ, et al. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther 2008; 15(13): 1007-16.
138. Kim TW, Lee JH, He L, et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65(1): 309-16.
139. Huang B, Mao CP, Peng S, Hung CF, Wu TC. RNA interferencemediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008; 19(8): 763-73.
140. Leachman SA, Tigelaar RE, Shlyankevich M, et al. Granulocytemacrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model. J Virol 2000; 74(18): 8700-8.
141. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998; 5(4): 231-52.
142. Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 2005; 116(2): 255-66.
143. Ohlschlager P, Quetting M, Alvarez G, Durst M, Gissmann L, Kaufmann AM. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequenceoptimized genetic adjuvants. Int J Cancer 2009; 125(1): 189-98.
144. Song XT, Evel-Kabler K, Rollins L, et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 2006; 3(1): e11.
145. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108(3): 804-11.
146. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007; 67(1): 371-80.
147. Chuang CM, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine 2009; 27(5): 684-9.
148. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997; 239(2): 389-401.
149. Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004; 22(3-4): 520-7.
150. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljestrom P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997; 13(17): 1487-95.
151. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 1998; 16(6): 562-5.
152. Hariharan MJ, Driver DA, Townsend K, et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 1998; 72(2): 950-8.
153. Cheng WF, Hung CF, Hsu KF, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002; 13(4): 553-68.
154. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M, Wu TC. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001; 8(5): 376-83.
155. Kim TW, Hung CF, Juang J, He L, Hardwick JM, Wu TC. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther 2004; 11(3): 336-42.
156. Varnavski AN, Young PR, Khromykh AA. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 2000; 74(9): 4394-403.
157. Herd KA, Harvey T, Khromykh AA, Tindle RW. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology 2004; 319(2): 237-48.
158. Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 2007; 7(10): 1473-86.
159. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des 2005; 11(27): 3485-500.
160. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 2000; 60(19): 5456-63.
161. Wang TL, Ling M, Shih IM, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000; 7(9): 726-33.
162. Peng S, Kim TW, Lee JH, et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005; 16(5): 584-93.
163. Kim JH, Kang TH, Noh KH, et al. Enhancement of dendritic cellbased vaccine potency by anti-apoptotic siRNAs targeting key proapoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009; 122(1): 58-67.
164. Yin R, Zheng W, Hao F, Yang XC, Zhong BY, Li QJ. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. J Dermatol Sci 2009; 55(2): 116-22.
165. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002; 346(22): 1752-3.
166. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129(9): 521-30.
167. Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006; 100(3): 469-78.
168. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008; 82(4): 1968-79.
169. NTU Hospital. Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited 2009 Nov 17]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00155766 NLM Identifier: NCT00155766.
170. Bubenik J. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours. Curr Cancer Drug Targets 2008; 8(3): 180-6.
171. Mikyskova R, Indrova M, Simova J, et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol 2004; 24(1): 161-7.
172. Hallez S, Detremmerie O, Giannouli C, et al. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 1999; 81(3): 428-37.
173. Chang EY, Chen CH, Ji H, et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000; 86(5): 725-30.
174. Indrova M, Bieblova J, Jandlova T, Vonka V, Pajtasz-Piasecka E, Reinis M. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and - deficient tumours. Int J Oncol 2006; 28(1): 253-9.
175. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57(10): 1569-77.
176. Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000; 18(19): 2015-22.
177. Wlazlo AP, Deng H, Giles-Davis W, Ertl HC. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther 2004; 11(6): 457-64.
178. Rittich S, Duskova M, Mackova J, Pokorna D, Jinoch P, Smahel M. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep 2005; 13(2): 311-7.
179. Lin CT, Hung CF, Juang J, et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther 2003; 8(4): 559-66.
180. Mackova J, Stasikova J, Kutinova L, et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 2006; 55(1): 39-46.
181. Kast WM. VEEV Replicon-based vaccines used in heterologous prime boost strategies induce lifelong protection againt cancer and therapy of cervical cancer in mice and robust cell-mediated immunity in rhesus macques. Vaccine Technology II, Barry C, Buckland, Merck & Co. Inc. John G. Aunins, Merck & Co. Inc. 2008; vol. P09.
182. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56(5): 739-45.
183. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18(2): 206-13.
184. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71(4): 630-7.
185. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7(10): 1118-22.
186. Goldberg MV, Maris CH, Hipkiss EL, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007; 110(1): 186-92.
187. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10(9): 942-9.
188. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13(7): 828-35.
189. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7(1): 41-51.
190. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419(6908): 734-8.
191. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004; 10(1): 15-8.
192. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5(3): 241-51.
193. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007; 30(1): 233-45.
194. Chuang CM, Monie A, Wu A, Hung CF. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci 2009; 16: 49.
195. Kang TH, Lee JH, Song CK, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007; 67(2): 802-11.
196. Sin JI, Kim JM, Bae SH, Lee IH, Park JS, Ryoo HM. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther 2009; 17(5): 906-13.
197. Amine A, Rivera S, Opolon P, et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One 2009; 4(3): e5018.
198. Van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 2009; 115(1): 69-74.
199. Coremans G, Snoeck R. Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPVassociated anal lesions. Expert Opin Pharmacother 2009; 10(8): 1343-52.
200. Tseng CW, Trimble C, Zeng Q, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009; 58(5): 737-48.
201. Tseng CW, Monie A, Trimble C, et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008; 26(34): 4314-9.
202. Tseng CW, Monie A, Wu CY, et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cellmediated antitumor immunity induced by DNA vaccination. J Mol Med 2008; 86(8): 899-908.